To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
Board Member
Keith Meister has served on has served on the Board of Directors at GeneDx (formerly Sema4) s since January 2022.
Currently, Keith is also Managing Partner and Chief Investment Officer of Corvex Management LP, which he founded in December 2010.
Prior to founding Corvex, Keith served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises from August 2003 to August 2010. From its launch in November 2004 to August 2010, he also served as Senior Managing Director of the General Partners of Icahn Partners LP and affiliated funds. Prior to joining the Icahn Organization, Keith served as Co‐President of J Net Ventures from January 2000 through September 2001. Prior to launching J Net Ventures, he worked at NorthStar Capital and Lazard Freres.
In addition to GeneDx, Keith currently serves on the Board of Directors for MGM Resorts and BetMGM. He has previously served as a director on numerous other public boards including Yum! Brands, Inc., The Williams Companies, The ADT Corporation, Ralcorp Holdings, and Motorola/Motorola Mobility, among others. He is also Chairman of the Board of Directors for Harlem Children’s Zone and a member of the Board of Trustees for the American Museum of Natural History.
Keith received an A.B. in government, cum laude, from Harvard College in 1995.
